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Abstract  
Cardiovascular disease (CVD), preventable through appropriate management of absolute CVD 
risk, disproportionately affects socioeconomically disadvantaged individuals. The aim of this 
study was to estimate absolute and relative socioeconomic inequalities in absolute CVD risk 
and treatment in the Australian population using cross-sectional representative data on 4,751 
people aged 45-74 from the 2011-12 Australian Health Survey. Poisson regression was used to 
calculate prevalence differences (PD) and ratios (PR) for prior CVD, high 5-year absolute risk of 
a primary CVD event and guideline-recommended medication use, in relation to 
socioeconomic position (SEP, measured by education). After adjusting for age and sex, the 
prevalence of high absolute risk of a primary CVD event among those of low, intermediate and 
high SEP was 12.6%, 10.9% and 7.7% (PD, low vs. high=5.0 [95% CI: 2.3, 7.7], PR=1.6 [1.2, 2.2]) 
and for prior CVD was 10.7%, 9.1% and 6.7% (PD=4.0 [1.4, 6.6], PR=1.6 [1.1, 2.2]). The 
proportions using preventive medication use among those with high primary risk were 21.3%, 
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19.5% and 29.4% for low, intermediate and high SEP and for prior CVD, were 37.8%, 35.7% and 
17.7% (PD=20.1 [9.7, 30.5], PR=2.1 [1.3, 3.5]). Proportions at high primary risk and not using 
medications among those of low, intermediate and high SEP were 10.6%, 8.8% and 4.7% and 
with prior CVD not using medications were 8.5%, 6.3% and 4.1%. Findings indicate substantial 
potential to prevent CVD and reduce inequalities through appropriate management of high 
absolute risk in the population. 
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Introduction 
Cardiovascular disease (CVD) is the leading cause of death globally and a leading contributor 
to morbidity.1 In Australia, CVD accounts for 12% of the total expenditure on health care, with 
estimated costs of $7.7 billion in 2008-09.2 Approximately 80% of CVD events can be prevented 
by modifying risk factors to reduce events.3, 4 In high income countries like Australia the 
prevalence of modifiable risk factors is known to be disproportionately high in disadvantaged 
groups, and individuals of low socioeconomic position are more likely to have a CVD event than 
those of high socioeconomic position.5-7 This inverse association is likely the result of a complex 
interplay between risk factors, including behavioural and biological factors, across the life-
course,7 and social determinants of health.8  
 
International guidelines (e.g.9, 10) recommend an absolute risk approach for the assessment 
and management of primary CVD risk. Absolute risk is quantified using a validated CVD risk 
calculator, whereby quantitative data on multiple factors that influence risk, including smoking 
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status, systolic blood pressure, blood lipid levels, and diabetes status, are applied to a person’s 
age- and sex-specific background level of absolute risk to predict an individual’s risk of having 
a CVD event in a given period of time (typically five or ten years).11 For people who have had a 
prior CVD event or who are at high absolute risk of primary CVD  event (>15% over 5 years in 
Australia) lifestyle modifications and treatment with blood pressure- and lipid-lowering 
therapies are generally recommended, unless contraindicated.10   
 
Although the links between socioeconomic position and individual CVD risk factors, morbidity 
and mortality have been demonstrated by studies internationally,12-16 there are no studies that 
have quantified absolute CVD risk in relation to socioeconomic position. Population-level data 
on variations in absolute CVD risk assessment and management are needed to inform 
population-level interventions and policies to prevent CVD and address inequalities. This paper 
aims to estimate the absolute and relative socioeconomic inequalities in absolute CVD risk and 
treatment of risk in Australia. 
 
Methods 
Study population 
Details on the data sources have been published previously.17 Briefly, we used data from 
participants in the 2011-12 Australian Bureau of Statistics Australian Health Survey18 aged 45-
74 years, and who provided data for the National Health Survey and biomedical data for the 
National Health Measures Survey, two components of the Australian Health Survey. All those 
that completed the National Health Measures Survey also completed the National Health 
Survey. The Australian Health Survey is a nationally representative survey of private 
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households in Australia (~97% coverage). Of the 30,329 participants eligible to participate in 
the National Health Measures Survey, 11,246 (37%) took part (47% of those aged 45-74 years).  
 
Outcomes: absolute CVD risk assessment and treatment 
The outcomes were prior CVD, high absolute risk of a primary CVD event, and use of preventive 
medications according to recommendations in national Australian guidelines. Prior CVD was 
self-reported as having had one or more of: ischaemic heart disease, angina, heart failure, 
oedema,   other   heart   disease   (including   atrial fibrillation/flutter), cerebrovascular disease, 
and diseases of arteries, arterioles and capillaries. People with prior CVD are considered to be 
at high risk of secondary CVD events. In participants without prior CVD, absolute risk of a 
primary CVD event over the next five years was estimated using the Australian National 
Vascular Disease Prevention Alliance risk assessment algorithm.10 Using this algorithm, some 
people are considered to be at clinically-determined high risk based on existing risk factors (for 
example, people with diabetes who are over 60 years old). For all other people, the 
Framingham CVD risk equation10, 11 was applied, with five-year risk categorised as low (<10%), 
moderate (10-15%) or high (>15%).10 Recommended treatment (according to Australian 
clinical guidelines10) for individuals at high absolute risk of a primary CVD event was defined as 
the use of blood pressure- and lipid-lowering medications, as reported in a medications review. 
For people with prior CVD, recommended treatment also included antithrombotic medication, 
as per Australian clinical guidelines.19-22 Medications were coded using the World Health 
Organization Anatomical Therapeutic Chemical (ATC) Classification System23 and included ATC 
codes: C02, C03, C07, C08 and C09 for blood pressure-lowering medications,  ATC code C10 
for lipid-lowering medications, and ATC code B01 for antithrombotic medication. 
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Main exposure: socioeconomic position 
Socioeconomic position was based on educational attainment ascertained from self-reported 
highest level of qualification and categorised as: high (university degree); intermediate 
(certificate, diploma or trade); or low (high school certificate or no qualifications). 
 
Statistical analysis 
The proportions with prior CVD and with low, moderate and high primary CVD risk were 
calculated, by socioeconomic position. We also summarised the distribution of individual CVD 
risk factors in those without a prior CVD event by socioeconomic position. We used Poisson 
regression with robust standard errors24, 25 to quantify absolute and relative inequalities in the 
prevalence of high absolute risk of primary CVD and of prior CVD, as well as in use of preventive 
treatments within each of these high risk groups. In the treatment analysis, we used data from 
the full National Health Survey dataset and included an additional 211 participants who 
reported having prior CVD and an additional 89 participants who had clinically determined high 
risk who were previously excluded due to missing biomedical data. Prevalence ratios (PR) were 
obtained directly from the Poisson regression coefficients, and post-estimation marginal 
effects were used to estimate the absolute prevalence differences, for each level of 
educational attainment in relation to the reference group (university degree). The models were 
adjusted sequentially, first for age and sex, and then additionally for region of residence (major 
cities, inner regional or other [outer regional and remote/very remote], measured using the 
Accessibility/Remoteness Index of Australia) and region of birth (Australia/New Zealand or 
other). We applied weights to the prevalence estimates to account for the sampling strategy 
and non-response.26 95% confidence intervals (95% CI) were calculated for all estimates. 
Analyses were performed using Stata version 13.1.27  
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Sensitivity analyses 
We undertook three sensitivity analyses, re-running the main models using alternative 
measures of socioeconomic position: (1) educational attainment measured using highest year 
of school completed (year 11/12 or equivalent; year 9/10 or equivalent; year 8 or below); (2) 
equivalised household income in quartiles; and (3) area-level disadvantage measured using the 
Index of Relative Socioeconomic Disadvantage (Socio-Economic Indexes for Areas28) in 
population-based quintiles. We also ran a post-hoc analysis to examine whether differences in 
medication use according to socioeconomic position varied by type of prior CVD. 
 
Ethics approval for the National Health Measures Survey data collection was provided by the 
Australian Government Department of Health Human Research Ethics Committee (ref: 
2/2011), with additional approval, for the current study, by the Australian National University 
Human Research Ethics Committee (ref: 2014/208). 
 
Results 
A total of 4,751 people were included in the main analysis after excluding participants with 
missing data on education (n=82, 1.5%) or on any variables needed for assessing absolute CVD 
risk (n=520, 9.7%). Forty-nine percent of the participants were male and the median age was 
59 years (interquartile range: 52-65 years). Overall, 24% of participants had a high 
socioeconomic position, 37% intermediate, and 38% had low socioeconomic position (Table 
1). Compared to people with the highest socioeconomic position, those of the lowest 
socioeconomic position were more likely to be older, have been born in Australia or New 
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Zealand, or be residing outside major cities (Table 1) and had a greater burden of CVD risk 
factors (Supplementary Table S1). 
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Table 1. Characteristics of the study population by socioeconomic position (N=4751), data from the 
2011-12 Australian National Health Survey 
 Socioeconomic position   
  Low Intermediate  High  Total 
 n=1825 n=1774 n=1152  N=4751 
Sex      
Male 43.2 57.6 45.1  49.3 
Female 56.9 42.4 54.9  50.7 
Age (years)   
 
 
 
45-49 14.8 23.9 26.6  21.1 
50-54 18.0 20.4 25.2  20.6 
55-59 17.4 19.1 18.1  18.2 
60-64 18.8 16.4 14.6  16.9 
65-69 17.5 11.2 10.5  13.4 
70-74 13.6 9.1 5.1  9.8 
Country of birth   
 
 
 
Australia or New Zealand 71.6 74.6 64.8  71.2 
Other 28.4 25.5 35.2  28.8 
Region of Residence   
 
 
 
Major cities 62.4 66.9 75.1  67.2 
Inner regional  25.9 23.0 19.1  23.2 
Other 11.7 10.1 5.7  9.7 
Notes: (1) Characteristics given as weighted percentages. (2) Socioeconomic position measured by level of 
educational attainment (low = high school certificate or no qualifications; intermediate = certificate, diploma or 
trade; and high = university degree). (3) Other region of residence includes outer regional and remote/very 
remote. 
 
Socioeconomic variation in absolute risk of a primary CVD event and prior CVD 
Overall, 11.0% (95% CI: 9.9, 12.2) of participants had a high absolute risk of a primary CVD 
event and 9.3% (8.3, 10.4) had prior CVD (Supplementary Table S2). The percentage of people 
with a high absolute CVD risk increased with decreasing socioeconomic position: of 
respondents with a high socioeconomic position 6.2% (4.7, 8.2) had a high absolute risk of a 
primary CVD event and 5.8% (4.3, 7.7) had prior CVD, compared with 11.2% (9.5, 13.2) and 
9.0% (7.3, 11.0) of respondents with an intermediate socioeconomic position, and 13.8% (11.9, 
16.0) and 11.7% (10.1, 13.7) of respondents with a low socioeconomic position 
(Supplementary Table S2). Age-sex adjusted prevalences are reported in Figure 1.  
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Figure 1. Age and sex adjusted prevalence of prior CVD and low, moderate and high absolute 5-year risk 
of primary CVD event by socioeconomic position among individuals in the Australian population aged 
45-74, data from the 2011-12 Australian Health Survey.  
CVD=cardiovascular disease. Notes: (1) Socioeconomic position measured by level of educational attainment 
(low = high school certificate or no qualifications; intermediate = certificate, diploma or trade; and high = 
university degree). (2) Absolute risk categorised according to five-year predicted CVD risk estimated using the 
Australian National Vascular Disease Prevention Alliance risk assessment algorithm, low risk=<10%, moderate 
risk=10-15%, high risk=>15%. (3) Percentages were weighted to account for the sampling strategy and non-
response. 
 
After adjusting for age and sex, the prevalence of high absolute risk of a primary CVD event 
and prior CVD increased linearly with decreasing socioeconomic position (test for trend, 
p=0.001 and p=0.005, respectively). The prevalence of high absolute risk of a primary CVD 
event was 3.3 (0.6, 5.9) percentage points higher among people with intermediate 
socioeconomic position and 5.0 (2.3, 7.7) percentage points higher among those with low 
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socioeconomic position, compared to those with a high socioeconomic position (Figure 2). The 
corresponding prevalence ratios were 1.4 (1.1, 1.9) and 1.6 (1.2, 2.2) (Figure 2). Further 
adjustment for country of birth and region of residence made little difference to the results 
(Supplementary Table S3). Patterns were similar for the outcome of prior CVD. After adjusting 
for age and sex, the prevalence of prior CVD was 2.4 (-0.3, 5.1) and 4.0 (1.4, 6.6) percentage 
points higher among those with an intermediate and low socioeconomic position, compared 
to those with a high socioeconomic position (Figure 2). The corresponding PRs were 1.4 (1.0, 
1.9) and 1.6 (1.1, 2.2) (Figure 2).  
 
 
Figure 2. Relative and absolute differences in prevalence of individual aged 45-74 years at high absolute 
risk of primary CVD and prior CVD by level of education, data from the 2011-12 Australian Health Survey 
Notes: (1) Socioeconomic position measured by level of educational attainment (low = high school certificate or 
no qualifications; intermediate = certificate, diploma or trade; and high = university degree). (2) Numbers are 
based on 4751 respondents. (3) Models are adjusted for age and sex. (4) Prevalence ratios are plotted. (5) 
Prevalences were weighted to account for the sampling strategy and non-response. (6) Absolute risk 
categorised according to five-year predicted CVD risk estimated using the Australian National Vascular Disease 
Prevention Alliance risk assessment algorithm, low risk=<10%, moderate risk=10-15%, high risk=>15%. 
 
Socioeconomic variation in treatment 
Of those at high absolute risk of a primary CVD event, 21.8% (95%CI: 17.2, 27.2) were taking 
both blood pressure- and lipid-lowering medications, 27.7% (22.8, 33.3) were taking one of 
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these medications, and half (50.5% [44.4, 56.5]) were taking neither (Supplementary Table S4). 
28.5% (15.8, 45.7) of those with a high socioeconomic position, 19.2% (12.5, 28.2) with an 
intermediate socioeconomic position and 21.8% (15.6, 29.7) with a low socioeconomic position 
were taking both medications (Supplementary Table S4), and after adjusting for age and sex 
the differences were not statistically significant (Figure 3). Among those with low, intermediate 
and high socioeconomic position respectively, the age-sex adjusted proportions of people at 
high primary risk and not using both medications were 10.6% (8.4, 12.8), 8.8% (6.8, 10.9) and 
4.7% (2.9, 6.4). 
 
 
Figure 3. Relative and absolute differences in prevalence and total number of individuals aged 45-74 
years at high absolute risk of primary CVD or with prior CVD using recommended medication by level of 
education, data from the 2011-12 Australian Health Survey 
Notes: (1) Socioeconomic position measured by level of educational attainment (low = high school certificate or 
no qualifications; intermediate = certificate, diploma or trade; and high = university degree). (2) Numbers are 
based on 426 respondents at high absolute risk of primary CVD and 716 respondents with prior CVD. (3) 
Prevalence ratios are plotted. (4) Proportions refer to those at high primary risk using both blood pressure- and 
lipid-lowering medications and those using blood pressure- and lipid-lowering, and antithrombotic medications 
among those with prior CVD. (5) Models are adjusted for age and sex. (6) Prevalences were weighted to account 
for the sampling strategy and non-response. (7) Absolute risk categorised according to five-year predicted CVD 
risk estimated using the Australian National Vascular Disease Prevention Alliance risk assessment algorithm, low 
risk=<10%, moderate risk=10-15%, high risk=>15%. 
 
12 
 
Among people with prior CVD, 34.3% (95%CI: 30.0-38.9) were taking the recommended 
medications, including 37.3% (31.3, 43.8) of those with a low and 36.5% (29.0, 44.7) of those 
with an intermediate socioeconomic position compared to 17.6% (10.6, 27.6) of those with a 
high socioeconomic position (Supplementary Table S4). After adjusting for age and sex, 
prevalence of recommended treatment was 18.0 (95%CI: 7.0, 29.0) and 20.1 (9.7, 30.5) 
percentage points higher among those with an intermediate and low socioeconomic position, 
compared to those with a high socioeconomic position (Figure 3). The corresponding 
prevalence ratios were 2.0 (1.2, 3.4) and 2.1 (1.3, 3.5). Additional adjustment for country of 
birth and region of residence made no material difference to the results (Supplementary Table 
S5). We observed the same pattern of results when we restricted the analysis to people who 
reported having prior CVD and had biomedical data to calculate absolute risk (results not 
shown). Among those with low, intermediate and high socioeconomic position respectively, 
the age-sex adjusted proportions of people with CVD and not using both medications were 
8.5% (6.5, 10.6), 6.3% (4.5, 8.1) and 4.1% (2.3, 5.9). 
 
Sensitivity analyses 
Results were broadly consistent when alternative measures of socioeconomic position (level 
of high school educational attainment, household income, and area level disadvantage) were 
used (Supplementary tables S6-S12). Prevalence of high absolute primary CVD risk and prior 
CVD increased with lower levels of socioeconomic position (Supplementary Tables S7 and S8). 
Using the alternative indicators of socioeconomic position, there were no clear patterns 
between treatment and socioeconomic position among those at high absolute risk of a primary 
CVD event (Supplementary Table S11), while in people with prior CVD, results were in the same 
direction as the main analysis but were not statistically significant (Supplementary Table S12). 
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There was little difference in the types of prior CVD reported between those with low, 
intermediate and high socioeconomic position (Supplementary Table S13) and prevalence 
ratios were slightly attenuated but still in the same direction when type of CVD was adjusted 
for in the analysis of treatment in those with prior CVD (Supplementary Table S14).    
 
Discussion 
In this nationally representative population-based Australian study, the prevalence of both 
high absolute CVD risk and established CVD increased with increasing levels of disadvantage. 
In those with no school qualifications versus a university education, the prevalence of 
established CVD and of high absolute risk of a primary CVD event were both 1.6 times higher, 
and in absolute terms, 4 and 5 percentage points higher, respectively. Treatment levels were 
low overall and varied by socioeconomic position. Overall, around one in five people with a 
high primary risk and one in three people with established CVD reported using both lipid- and 
blood pressure-lowering medications. However, among people with established CVD the use 
of recommended preventive medications was twice as high in those with low versus high 
socioeconomic position. Despite this, around two times as many people of low compared to 
high socioeconomic position were at high absolute risk of a primary CVD event or had existing 
CVD and were not using lipid- and blood pressure-lowering medications.  
 
This is the first study, to our knowledge, to investigate how absolute CVD risk and treatment 
varies according to socioeconomic position. Our findings are consistent with previous findings 
that incidence and prevalence of CVD is higher in people of low compared to high 
socioeconomic position.29-32 The observed inverse association between socioeconomic 
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position and treatment in people with prior CVD were contrary to our expectation that, 
consistent with findings of inequalities in care33, people with a low socioeconomic position 
would be less likely to receive treatment than those with a high socioeconomic position. 
However, this finding is not without precedent. Two previous Australian studies found age-
adjusted rates of statin prescribing were highest in the most socioeconomically disadvantaged 
people.34, 35  
 
There is limited evidence of socioeconomic variations in preventive treatment use in people 
with prior CVD from previous international studies. Findings from an international systematic 
review and meta-analysis found socioeconomic-related differences in treatment following 
hospitalisation for acute coronary syndrome varied by medication type.36 Overall they found 
no inequalities in prescribing of aspirin, a 20% lower prevalence of lipid-lowering prescriptions 
and a 16% lower prevalence of beta-blocker prescriptions but a 13% higher prevalence of ACE 
inhibitor prescriptions, in the people with the lowest compared to the highest socioeconomic 
position.36 Studies of secondary prevention prescribing in people with prior CVD in Denmark, 
England and Scotland found no overall evidence of differences in prescribing by socioeconomic 
status.37-39 The study in Denmark observed an increased prevalence of statin prescribing in 
men (but not women) with higher compared to lower socioeconomic position measured by 
occupation in 1995 but this finding was attenuated and no longer statistically significant using 
data from 1999.39  
 
It is not clear why there might be an inverse association between socioeconomic position and 
use of preventive medications in people with established CVD in Australia, although this does 
not appear to be driven by differences in type of CVD. Our findings may reflect, at least in part, 
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differential subsidisation of medications under Australian’s universal healthcare system, 
Medicare. Generally, people with a Medicare card (Australian and New Zealand citizens and 
permanent residents/visa holders) pay a co-payment for prescription medicines under the 
Pharmaceutical Benefits Scheme, but this co-payment is substantially lower for people who 
are eligible for a concession, including people with low incomes and pensioners. However, this 
does not explain why we did not observe socioeconomic variation in use of preventative 
medications for those at high primary risk.  
 
Our study has three crucial strengths compared to previous studies examining CVD treatment. 
First, we were able to examine socioeconomic variation in treatment separately for people 
with prior CVD and those at high absolute risk of a primary CVD event. Second, we examined 
medication use according to recommendations in Australian national guidelines which 
recommend the concurrent use of multiple medications to lower risk. Third, we had 
information on a range of indicators of socioeconomic position allowing us to test the 
robustness of the results to different SEP measures.  
 
Although we observed socioeconomic variation in the prevalence of prior CVD and high 
absolute CVD risk, we did not explicitly quantify which CVD risk factors were the main 
contributing factors to these inequalities. In our sample, those of the lowest compared with 
the highest socioeconomic position had a higher prevalence of many CVD risk factors, including 
smoking, diabetes and systolic blood pressure, suggesting these factors are key contributors 
to the observed socioeconomic variation. This is consistent with evidence that individual CVD 
risk factors are elevated in people with lower socioeconomic position,40, 41 and that most of the 
socioeconomic position-CVD relationship is  accounted for by traditional CVD risk factors.40, 42  
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This is the first study, to our knowledge, to use nationally representative data from Australia 
to estimate socioeconomic inequalities in the prevalence of absolute CVD risk and 
recommended treatment use according to national guidelines. This is important as 
understanding variations in the prevalence of high absolute CVD risk provides insights about 
the potential to target population-based interventions and policies to improve primary 
prevention of CVD events. Access to biomedical data allowed for the calculation of absolute 
risk according to the National Vascular Disease Prevention Alliance algorithm10 and we tested 
the robustness of our findings using a range of individual-level socioeconomic indicators.  
 
In addition to these strengths, our study has some limitations. First, the study is cross-sectional 
and since treatment may have lowered absolute risk, the results cannot be used to draw 
conclusions of overtreatment in low risk groups. Second, for some analyses, sample sizes were 
small resulting in low power to observe statistically significant associations. Third, a small 
proportion of individuals may not be prescribed some medications due to contraindications. 
However, given we examined broad classes of medications this is likely to only be an issue for 
a very small subset of participants and is unlikely to impact interpretation of the results. Finally, 
some of the key variables, including socioeconomic position and prior CVD, were self-reported. 
This may have resulted in some misclassification, however the direction and extent to which 
this would bias the results is unknown.  
 
Our findings of increasing levels of high absolute CVD risk with increasing levels of disadvantage 
and low levels of treatment among high risk individuals suggest there is huge potential to 
prevent CVD events in the population through appropriate management of absolute risk. 
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Further, given the higher prevalence of untreated individuals at high absolute risk among those 
of lower socioeconomic position, treating according to absolute risk should result in reductions 
in absolute inequalities in CVD.  
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Table S1. Distribution of CVD risk factors in the population without prior CVD by socioeconomic position 
(N=4246) 
 Socioeconomic position   
  High Intermediate Low  Total  
Factors included in NVDPA algorithm       
Smoking Status  
   
 
 
Never  57.3 45.1 45.7  48.3 
Former 36.8 41.4 39.1  39.4 
Current 5.9 13.5 15.2  12.3 
Systolic Blood Pressure (mmHg)  
   
 
 
Normal (<120)  45.1 38.5 33.1  38.2 
Prehypertension (120-<140) 34.7 38.5 40.1  38.2 
Hypertension stage (≥140) 20.1 23.0 26.8  23.7 
Diastolic Blood Pressure (mmHg)  
   
 
 
Normal and pre-hypertension (<90)  85.8 83.4 83.6  84.0 
Hypertension stages 1 & 2 (90-<110)  14.2 16.2 15.9  15.6 
Hypertension crisis (>=110)  N/A 0.4 0.6  0.4 
High Density Lipoprotein Cholesterol (mmol/L) 
   
 
 
>=1.0 92.0 86.7 90.5  89.4 
<1.0  8.0 13.4 9.5  10.7 
Total Cholesterol (mmol/L)  
   
 
 
<4.0 4.2 6.3 7.2  6.1 
4.0-7.5 94.4 91.8 91.0  92.1 
>7.5  1.4 2.0 1.8  1.8 
Total Cholesterol:HDL-C ratio 
   
 
 
<4.5 69.1 66.7 66.5  67.2 
4.5-<6.0 24.7 24.8 24.8  24.8 
>=6.0  6.2 8.6 8.7  8.1 
Diabetes  3.5 9.4 10.3  8.3 
Diabetes with microalbuminuria  N/A N/A 2.6  1.6 
Chronic Kidney Disease  N/A N/A 0.6  0.5 
Additional risk factors       
Low Density Lipoprotein Cholesterol (mmol/L) 
   
 
 
<2.0 1.8 4.5 5.0  4.0 
2-3.5  57.2 57.4 53.4  55.9 
>3.5  40.9 38.1 41.7  40.1 
Body mass index 
   
 
 
Normal / underweight  37.9 24.4 27.0  28.6 
Overweight  40.0 41.5 35.9  39.1 
Obese 22.1 34.1 37.2  32.3 
Waist Circumference  
   
 
 
Not at risk  34.5 24.7 22.5  26.3 
At risk 65.5 75.3 77.5  73.8 
Physical Activity  
   
 
 
High  18.7 12.6 7.2  12.1 
Moderate  37.5 32.2 30.2  32.7 
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 Socioeconomic position   
  High Intermediate Low  Total  
Low  33.3 35.7 39.2  36.4 
Sedentary  10.6 19.6 23.4  18.8 
Notes: (1) Characteristics given as percentages. (2) Socioeconomic position measured by level of educational 
attainment (low = high school certificate or no qualifications; intermediate = certificate, diploma or trade; and 
high = university degree). (3) N/A = numbers too small to be released. Number of missing cases: LDL cholesterol 
830; BMI 102; waist circumference 77; physical activity 15.  
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Table S2. Prevalence and estimated number of individuals in the Australian population aged 45-74 with low, moderate and high absolute 5-year risk of primary 
CVD or prior CVD by socioeconomic position  
 5 Year Absolute Risk Prior CVD 
  Low Moderate High 
 
  % (95%CI) n ('000)  % (95%CI) n ('000)  % (95%CI) n ('000)  % (95%CI) n ('000)  
Socioeconomic position         
High  82.15 (79.15 -84.80) 1238 5.86 (4.33-7.89) 88 6.21 (4.71-8.15) 94 5.78 (4.32-7.70) 87 
Intermediate  69.55 (66.65-72.30) 1755 10.22 (8.50-12.50) 258 11.23 (9.53-13.20) 283 9.00 (7.33-10.99) 227 
Low 66.39 (63.54-69.13) 1596 8.06 (6.61-9.78) 194 13.81 (11.88-15.99) 332 11.74 (10.05-13.68) 282 
Total  71.32 (69.61-72.97) 4588 8.39 (7.42-9.48) 540 11.02 (9.94-12.20) 709 9.27 (8.26-10.39) 596 
Notes: (1) Socioeconomic position measured by level of educational attainment (low = high school certificate or no qualifications; intermediate = certificate, diploma or trade; 
and high = university degree). 
Table S3. Relative and absolute differences in prevalence of individuals aged 45-74 years at high absolute risk of primary CVD and prior CVD by socioeconomic 
position 
  Age-sex adjusted 
prevalence  
(95%CI) 
Model 1  Model 2  
  
Prevalence difference 
(95%CI) 
Prevalence ratio  
(95%CI) 
Prevalence difference 
(95%CI) 
Prevalence ratio  
(95%CI) 
High Primary Risk      
Socioeconomic position      
High 7.68 (5.67-9.70) 0.00 1.00 0.00 1.00 
Intermediate  10.94 (9.26-12.62) 3.26 (0.61-5.91) 1.42 (1.05-1.93) 3.55 (0.92-6.18) 1.47 (1.08-2.00) 
Low 12.64 (10.87-14.40) 4.95 (2.26-7.65) 1.64 (1.22-2.22) 5.13 (2.46-7.81) 1.68 (1.25-2.27) 
Prior CVD       
Socioeconomic position      
High 6.72 (4.81-8.63) 0.00 1.00 0.00 1.00 
Intermediate  9.09 (7.27-10.91) 2.37 (-0.31-5.05) 1.35 (0.95-1.93) 2.08 (-0.64-4.79) 1.30 (0.91-1.85) 
Low 10.69 (9.01-12.37) 3.97 (1.38-6.56) 1.59 (1.14-2.21) 3.72 (1.08-6.36) 1.54 (1.10-2.14) 
Notes: (1) Socioeconomic position measured by level of educational attainment (low = high school certificate or no qualifications; intermediate = certificate, diploma or trade; 
and high = university degree). (2) Model 1 is adjusted for age and sex (presented in main text); Model 2 is further adjusted for country of birth and region of residence 
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Table S4. Proportion of individuals aged 45-74 years at high absolute risk of primary CVD or with prior CVD by treatment status and socioeconomic position 
  No treatment Less than recommended treatment Recommended treatment  
  % (95%CI) n('000) % (95%CI) n('000) % (95%CI) n('000) 
High Primary Risk (n=426)       
Socioeconomic position   
      
High 49.14 (32.92-64.52) 29 22.39 (11.85-38.22) 13 28.47 (15.84-45.71) 17 
Intermediate  53.94 (44.15-63.43) 82 26.87 (19.51-35.77) 41 19.19 (12.53-28.24) 29 
Low 48.17 (39.50-56.95) 94 30.03 (22.83-38.37) 58 21.80 (15.57-29.65) 42 
Total  50.48 (44.44-56.51) 205 27.74 (22.83-33.25) 112 21.78 (17.17-27.21) 88 
Prior CVD (n=716)        
Socioeconomic position        
High 26.38 (17.06-38.43) 24 56.06 (43.68-67.74) 52 17.55 (10.61-27.63) 16 
Intermediate  12.99 (8.35-19.66) 30 50.50 (42.43-58.55) 117 36.51 (29.00-44.74) 85 
Low 12.80 (9.04-17.83) 44 49.87 (43.42-56.32) 173 37.33 (31.27-43.82) 130 
Total  14.74 (11.71-18.39) 99 50.94 (46.24-55.62) 342 34.32 (29.98-38.93) 230 
Notes: (1) Socioeconomic position measured by level of educational attainment (low = high school certificate or no qualifications; intermediate = certificate, diploma or trade; 
and high = university degree). (2) Recommended treatment for those at high primary risk is receiving blood pressure- and lipid-lowering medications. For those with prior 
CVD, recommended treatment is receiving blood pressure lowering, lipid lowering and antithrombotic medication. 
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Table S5. Relative and absolute differences in prevalence and total number of individuals aged 45-74 years at high absolute risk of primary CVD or prior CVD 
receiving recommended treatment by socioeconomic position 
 Age-sex adjusted 
prevalence  
(95%CI) 
Model 1  Model 2  
 
Prevalence difference 
(95%CI) 
Prevalence ratio  
(95%CI) 
Prevalence difference 
(95%CI) 
Prevalence ratio  
(95%CI) 
High Primary Risk (n=426)      
Socioeconomic position      
High 29.38 (13.77-45.00) 0.00 1.00 0.00 1.00 
Intermediate  19.51 (11.65-27.38) -9.87 (-27.46-7.72) 0.66 (0.34-1.30) -8.02 (25.78-9.73) 0.71 (0.35-1.44) 
Low 21.32 (14.69-27.95) -8.06 (-24.89-8.76) 0.73 (0.39-1.34) -6.81 (-23.33-9.71) 0.76 (0.41-1.41) 
Prior CVD (n=716)      
Socioeconomic position      
High 17.71 (9.45-25.97) 0.00 1.00 0.00 1.00 
Intermediate  35.70 (28.39-43.02) 17.99 (6.98-29.01) 2.02 (1.21-3.35) 18.37 (7.49-29.24) 2.07 (1.23-3.47) 
Low 37.81 (31.50-44.11) 20.10 (9.69-30.50) 2.13 (1.30-3.51) 21.04 (10.54-31.55) 2.22 (1.34-3.70) 
Notes: (1) Socioeconomic position measured by level of educational attainment (low = high school certificate or no qualifications; intermediate = certificate, diploma or trade; 
and high = university degree). (2) Model 1 is adjusted for age and sex; Model 2 is further adjusted for country of birth and region of residence. (3) Proportions refer to the 
proportion of those at high primary risk receiving both blood pressure- and lipid-lowering medications and those with prior CVD receiving blood pressure lowering, lipid 
lowering and antithrombotic medication. 
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Table S6. Prevalence and estimated number of individuals in the Australian population aged 45-74 years with low, moderate and high absolute 5-year risk of 
primary CVD or prior CVD according to different indicators of socioeconomic position (N=4751).  
  Absolute Primary CVD Risk  Prior CVD 
 Low Moderate  High   
  % (95%CI) n ('000) % (95%CI) n('000) % (95%CI) n ('000) % (95%CI) n ('000) 
Total  71.32 (69.93-72.68) 4588 8.39 (7.23-9.72) 540 11.02 (10.04-12.08) 709 9.27 (8.32-10.32) 596 
High school education          
Yr11-12 77.85 (75.82-79.75) 2582 6.59 (5.41-8.00) 218 8.24 (6.98-9.71) 273 7.33 (6.12-8.75) 243 
Yr9-10 68.30 (65.49-70.98) 1706 10.67 (8.75-12.96) 267 11.39 (9.64-13.42) 285 9.64 (7.95-11.63) 241 
Yr8-none 48.54 (42.50-54.61) 300 8.86 (5.45-14.09) 55 24.38 (19.05-30.65) 151 18.22 (3.71-23.80) 113 
Household income         
Richest  81.03 (77.50-84.13) 1258 7.31 (5.36-9.89) 113 6.81 (5.03-9.15) 106 4.85 (3.31-7.06) 75 
3 78.38 (74.63-81.70) 1233 7.96 (5.90-10.65) 125 6.46 (4.67-8.87) 102 7.21 (5.25-9.81) 113 
2 72.95 (69.52-76.12) 1083 8.10 (6.34-10.28) 120 10.13 (8.10-12.59) 150 8.83 (6.94-11.16) 131 
Poorest 55.63 (52.59-58.63) 1014 9.93 (8.35-11.77) 181 19.26 (16.96-21.80) 351 15.18 (13.15-17.45) 277 
Area level disadvantage        
Highest  78.41 (74.92-81.53) 1140 8.16 (6.28-10.56) 119 7.06 (5.20-9.51) 103 6.37 (4.74-8.50) 93 
4 74.71 (70.91-78.17) 943 7.46 (5.55-9.96) 94 10.51 (8.22-13.35) 133 7.32 (5.42-9.81) 92 
3 71.78 (67.92-75.35) 984 8.53 (6.36-11.36) 117 10.61 (8.51-13.17) 145 9.07 (6.99-11.70) 124 
2 69.58 (65.72-73.18) 850 9.66 (7.45-12.43) 118 11.88 (9.54-14.71) 145 8.88 (6.95-11.27) 108 
Lowest  59.72 (55.30-63.99) 673 8.17 (6.23-10.66) 92 16.25 (13.35-19.62) 183 15.86 (12.84-19.44) 179 
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Table S7. Relative and absolute differences in prevalence of individuals aged 45-74 years at high 
absolute risk of primary CVD by different indicators of socioeconomic position (N=4751) 
  
Age-sex adjusted 
prevalence high risk 
(95%CI) 
Prevalence difference 
(95%CI)  
Prevalence ratio  
(95%CI) 
High school education    
Yr11-12 9.80 (8.26-11.34) 0.00 1.00 
Yr9-10 10.74 (9.17-12.30) 0.94 (-1.29-3.16) 1.10 (0.88-1.36) 
Yr8-none 15.18 (11.84-18.52) 5.38 (1.67-9.09) 1.55 (1.18-2.04) 
Household income    
Richest  8.80 (6.28-11.31) 0.00 1.00 
3 8.42 (5.85-10.99) -0.37 (-3.93-3.18) 0.96 (0.63-1.45) 
2 10.11 (7.96-12.26) 1.31 (-2.02-4.65) 1.15 (0.80-1.65) 
Poorest  13.84 (11.96-15.72) 5.04 (1.80-8.28) 1.57 (1.14-2.18) 
Area level disadvantage   
Highest 7.33 (5.20-9.45) 0.00 1.00 
4 11.05 (8.66-13.45) 3.73 (0.52-6.93) 1.51 (1.05-2.17) 
3 11.04 (8.81-13.26) 3.71 (0.62-6.80) 1.51 (1.06-2.15) 
2 11.52 (9.09-13.94) 4.19 (0.96-7.41) 1.57 (1.10-2.25) 
Lowest 14.58 (12.04-17.13) 7.26 (3.96-10.55) 1.99 (1.42-2.79) 
Notes: (1) Models are adjusted for age and sex.  
 
Table S8. Relative and absolute differences in prevalence of individuals aged 45-74 years with prior CVD 
by different indicators of socioeconomic position (N=4751) 
  
Age-sex adjusted prevalence 
prior CVD (95%CI) 
Prevalence difference 
(95%CI)  
Prevalence ratio  
(95%CI) 
High school education    
Yr11-12 8.36 (6.85-9.86) 0.00 1.00 
Yr9-10 9.10 (7.47-10.72) 0.74 (-1.50-2.98) 1.09 (0.84-1.41) 
Yr8-none 12.81 (9.62-16.00) 4.45 (0.91-8.00) 1.53 (1.12-2.09) 
Household income    
Richest  5.72 (3.56-7.88) 0.00 1.00  
3 8.83 (6.07-11.60) 3.12 (-0.32-6.55) 1.55 (0.96-2.50) 
2 8.91 (6.84-10.97) 3.19 (0.23-6.15) 1.56 (1.00-2.42) 
Poorest  11.72 (9.71-13.72) 6.00 (2.89-9.11) 2.05 (1.33-3.16) 
Area Level disadvantage   
Highest 6.58 (4.69-8.47) 0.00 1.00 
4 7.58 (5.41-9.75) 1.00 (-1.87-3.87) 1.15 (0.77-1.73) 
3 9.30 (6.94-11.65) 2.72 (-0.31-5.74) 1.41 (0.96-2.07) 
2 8.70 (6.66-10.74) 2.12 (-0.66-4.90) 1.32 (0.91-1.92) 
Lowest 14.60 (11.44-17.76) 8.02 (4.32-11.72) 2.22 (1.55-3.18) 
Notes: (1) Models are adjusted for age and sex.  
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Table S9. Proportion of total individuals aged 45-74 years at high absolute risk of primary CVD by treatment status and different indicators of socioeconomic position 
(n=426)  
 No treatment Less than recommended treatment Recommended treatment 
 % (95%CI) n('000) % (95%CI) n('000) % (95%CI) n('000) 
Total  50.48 (44.44-56.51) 205 27.74 (22.83-33.25) 112 21.78 (17.17-27.21) 88 
High school education       
Yr11-12 52.93 (43.48-62.18) 88 26.80 (19.43-35.72) 44 20.26 (13.27-29.68) 34 
Yr9-10 48.38 (38.82-58.06) 77 30.09 (22.28-39.24) 48 21.53 (14.88-30.12) 34 
Yr8-none 49.61 (36.29-63.00) 40 24.98 (15.68-37.37) 20 25.40 (15.71-38.36) 20 
Household income        
Richest  49.13 (33.82-64.61) 38 29.23 (17.57-44.45) 23 21.64 (11.16-37.77) 17 
3 66.78 (48.15-81.31) 30 22.89 (10.78-42.17) 10 10.34 (4.37-22.54) 5 
2 58.91 (45.66-70.98) 50 24.53 (14.92-37.60) 21 16.56 (9.49-27.30) 14 
Poorest  43.65 (35.98-51.63) 86 29.64 (23.18-37.03) 58 26.71 (19.93-34.79) 53 
Area level disadvantage        
Highest  58.70 (42.94-72.85) 42 22.67 (12.25-38.11) 16 18.63 (9.34-33.74) 13 
4 43.85 (31.27-57.27) 33 38.69 (26.42-52.58) 29 17.46 (9.27-30.47) 13 
3 57.74 (45.00-69.53) 47 22.15 (13.58-34.01) 18 20.11 (12.33-31.04) 16 
2 45.90 (33.33-59.01) 37 30.78 (20.17-43.90) 25 23.32 (13.73-36.78) 19 
Lowest 47.28 (34.99-59.91) 45 25.15 (17.06-35.45) 24 27.57 (17.54-40.52) 27 
Notes: (1) Recommended treatment for those at high primary risk is use of blood pressure- and lipid-lowering medications. 
32 
 
Table S10. Proportion of total individuals aged 45-74 years with prior CVD by treatment status and different indicators of socioeconomic position (n=716) 
 No treatment Less than recommended treatment Recommended treatment 
 % (95%CI) n('000) % (95%CI) n('000) % (95%CI) n('000) 
Total  14.74 (11.71-18.39) 99 50.94 (46.24-55.62) 342 34.32 (29.98-38.93) 230 
High school education       
Yr11-12 20.27 (14.83-27.06) 46 53.82 (46.04-61.41) 123 25.92 (19.84-33.09) 59 
Yr9-10 14.18 (9.81-20.08) 41 48.71 (41.70-55.77) 142 37.11 (30.51-44.23) 108 
Yr8-none 7.42 (3.27-15.98) 11 50.89 (40.51-61.18) 77 41.69 (31.80-52.31) 63 
Household income        
Richest  19.28 (12.18-29.14) 26 50.55 (39.43-61.62) 67 30.18 (20.92-41.39) 40 
3 29.70 (17.30-46.03) 24 46.24 (32.53-60.54) 37 24.07 (14.18-37.81) 19 
2 14.79 (9.15-23.04) 21 52.38 (41.75-62.8) 76 32.83 (23.37-43.92) 47 
Poorest 8.99 (6.27-12.74) 28 51.64 (45.30-57.92) 162 39.37 (33.32-45.76) 124 
Area level disadvantage       
Highest  14.27 (8.22-23.64) 16 54.55 (43.1-65.53) 62 31.18 (21.76-42.47) 35 
4 18.69 (10.93-30.10) 22 49.83 (38.40-61.28) 58 31.48 (21.91-42.93) 36 
3 16.17 (9.85-25.39) 23 51.28 (41.20-61.26) 73 32.55 (23.96-42.51) 46 
2 15.97 (9.84-24.86) 20 47.72 (38.06-57.55) 61 36.32 (27.16-46.59) 46 
Lowest  10.30 (5.99-17.17) 18 51.43 (41.88-60.87) 89 38.27 (29.30-48.11) 66 
Notes: (1) Recommended treatment for those with prior CVD is use of blood pressure- and lipid-lowering medications and antithrombotic medications. 
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Table S11. Relative and absolute differences in prevalence and total number of individuals at high 
absolute risk of primary CVD receiving recommended treatment by different indicators of 
socioeconomic position (n=426) 
  
Age-sex adjusted prevalence  
(95%CI) 
Prevalence difference 
(95%CI) 
Prevalence ratio  
(95%CI) 
High school education    
Yr11-12 21.98 (13.25-30.70) 0.00 1.00 
Yr9-10 20.96 (13.60-28.32) -1.02 (-12.51-10.48) 0.95 (0.56-1.63) 
Yr8-none 22.95 (12.83-33.07)  0.97 (-12.48-14.43) 1.04 (0.57-1.90) 
Household income 
  
Richest 22.76 (8.75-36.77) 0.00 1.00 
3 12.62 (1.97-23.28) -10.14 (-27.89-7.61) 0.55 (0.19-1.59) 
2 17.24 (7.81-26.66) -5.53 (-22.57-11.52) 0.76 (0.33-1.74) 
Poorest  24.77 (17.84-31.70) 2.01 (-13.44-17.45) 1.09 (0.56-2.13) 
Area level disadvantage    
Highest  17.35 (6.00-28.70) 0.00 1.00 
4 18.00 (7.09-28.91) 0.65 (-15.06-16.36) 1.04 (0.42-2.53) 
3 20.63 (11.47-29.79) 3.28 (-11.36-17.92) 1.19 (0.54-2.63) 
2 24.65 (12.79-36.51) 7.30 (-9.19-23.78) 1.42 (0.63-3.22) 
Lowest  26.62 (15.85-37.40) 9.27 (-6.40-24.95) 1.53 (0.71-3.32) 
Notes: (1) Proportion refers to those at high absolute risk of CVD who receive recommended treatment (blood 
pressure- and lipid lowering medications). (2) Models are adjusted for age and sex. 
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Table S12. Relative and absolute differences in prevalence and total number of individuals with prior 
CVD using recommended treatment by different indicators of socioeconomic position (n=716)  
  
Age-sex adjusted prevalence 
(95%CI) 
Prevalence difference 
(95%CI) 
Prevalence ratio  
(95%CI) 
High school education     
Yr11-12 26.58 (19.85-33.30) 0.00 1.00 
Yr9-10 38.15 (31.41-44.88) 11.57 (2.03-21.11) 1.44 (1.05-1.96) 
Yr8-none 38.25 (28.25-48.26) 11.68 (-0.67-24.03) 1.44 (0.99-2.09) 
Household income    
Richest 31.86 (21.26-42.45) 0.00 1.00 
3 24.35 (11.99-36.72) -7.50 (-24.02-9.01) 0.76 (0.41-1.42) 
2 33.41 (23.22-43.61) 1.56 (-13.18-16.29) 1.05 (0.67-1.65) 
Poorest  38.09 (32.08-44.10) 6.24 (-5.85-18.32) 1.20 (0.83-1.72) 
Area level disadvantage    
Highest  30.64 (20.50-40.78) 0.00 1.00 
4 30.94 (21.06-40.82) 0.30 (-13.85-14.44) 1.01 (0.64-1.60) 
3 34.67 (24.59-44.74) 4.03 (-10.31-18.37) 1.13 (0.72-1.76) 
2 35.49 (26.07-44.92) 4.86 (-8.96-18.67) 1.16 (0.76-1.77) 
Lowest  37.89 (29.13-46.66) 7.26 (-6.14-20.65) 1.24 (0.83-1.85) 
Notes: (1) Proportion refers to those with prior CVD who are receiving recommended treatment (blood 
pressure- and lipid lowering medication and antithrombotic medication). (2) Models are adjusted for age and 
sex.  
 
Table S13.  Age and sex adjusted percentage of respondents with prior CVD reporting each type of CVD, 
according to socioeconomic position 
 Socioeconomic position 
 High  Intermediate  Low  
Angina  21.69 24.93 25.41 
Heart attack  23.31 31.29 36.12 
Other heart disease  11.77 12.21 5.51 
Stroke/ cerebrovascular disease  21.32 21.84 21.52 
Heart failure  8.09 7.84 9.11 
Oedema  17.03 14.64 16.54 
Disease of arteries/ veins/ 
capillaries  
31.99 22.44 23.28 
Notes: (1) Socioeconomic position measured by level of educational attainment (low = high school certificate or 
no qualifications; intermediate = certificate, diploma or trade; and high = university degree)
Table S14. Relative and absolute differences in prevalence and total number of individuals aged 45-74 years 
with prior angina, heart attack or stroke receiving recommended treatment by socioeconomic position 
  Age-sex adjusted 
prevalence  
(95%CI) 
 
  
Prevalence difference 
(95%CI) 
Prevalence ratio  
(95%CI) 
Socioeconomic position    
High 24.18 (11.49-36.88) 0.00 1.00 
Intermediate  40.54 (31.27-49.82) 16.36 (0.64-32.08) 1.68 (0.94-2.98) 
Low 39.23 (31.36-47.09) 15.04 (0.11-29.98) 1.62 (0.92-2.85) 
Notes: (1) Socioeconomic position measured by level of educational attainment (low = high school certificate or no 
qualifications; intermediate = certificate, diploma or trade; and high = university degree). (2) Model is adjusted for age 
and sex; Model 2 is further adjusted for country of birth and region of residence. (3) Numbers are based on 462 
respondents. 
 
 
